Asia Pacific Forced Oscillometry Market is expected to reach US$ 13,075.3 Thousand by 2034

According to The Insight Partners\' research, the Asia Pacific Forced Oscillometry Market was valued at US$ 7,853.0 Thousand in 2025 and is expected to reach US$ 13,075.3 Thousand by 2034, registering a CAGR of 5.9% from 2026 to 2034.

Increasing effort-independent testing advantage and rise of hybrid oscillometry systems are among the critical factors attributed to driving the Asia Pacific forced oscillometry market growth.

The effort-independent character of FOT constitutes one of its strongest competitive advantages over conventional spirometry, enabling reliable lung-function assessment in populations historically underserved by standard testing. Unlike spirometry, which demands maximal forced expiratory manoeuvres, coordinated effort, and repeated practice, FOT superimposes small pressure oscillations on normal tidal breathing for 10-20 seconds, requiring only passive cooperation. This fundamental difference translates into markedly higher feasibility rates. In a 2024 study of school-age children with bronchopulmonary dysplasia performing home-based tests, 98% completed oscillometry compared with 77% for spirometry (odds ratios 5.31-12.5 favoring oscillometry). In preschool children (3-5 years), FOT success rates range from 57% to 100% across published series, outperforming spirometry where cooperation is limited or absent. The advantage is equally pronounced in the elderly and in patients with neuromuscular weakness, cognitive impairment, or acute respiratory distress, groups in which spirometry failure rates frequently exceed 30-50%. Clinically, this translates into broader applicability: FOT reliably detects small-airway dysfunction in 25-40% of pediatric asthma cases missed by spirometry, monitors treatment response in cystic fibrosis, and identifies early airway changes in asymptomatic smokers. Its noninvasive, quick, and repeatable nature also supports serial monitoring without patient fatigue, facilitating home or primary-care use. By removing the effort barrier that excludes millions of vulnerable patients from objective lung-function evaluation each year, FOT expands diagnostic access, improves equity in respiratory care, and meets the real-world needs of pediatric, geriatric, and critically ill populations, driving its integration into routine clinical pathways.

On the contrary, the high equipment and maintenance costs hamper the growth of the Asia Pacific forced oscillometry market.

Asia Pacific Forced Oscillometry Market Segmentation Analysis:

• By Product, the Asia Pacific Forced Oscillometry Market is segmented into Device and Accessories. The Device segment is projected to expand at a CAGR of 4.8% during 2026 - 2034.
• By Device For Product, the Asia Pacific Forced Oscillometry Market is segmented into Desktop and Portable. The Desktop segment is projected to expand at a CAGR of 4.6% during 2026 - 2034.
• By Accessories For Product, the Asia Pacific Forced Oscillometry Market is segmented into Filters, Nose Clip, Support Arms, and Other Accessories. The Filters segment is projected to expand at a CAGR of 8.5% during 2026 - 2034.
• By Application, the Asia Pacific Forced Oscillometry Market is segmented into Asthma, COPD, and Other Applications. The Asthma segment is projected to expand at a CAGR of 6.3% during 2026 - 2034.
• By End User, the Asia Pacific Forced Oscillometry Market is segmented into Hospitals and Clinics, Diagnostic Laboratories, and Other End users. The Hospitals and Clinics segment is projected to expand at a CAGR of 6.1% during 2026 - 2034.

By country, the Asia Pacific Forced Oscillometry Market is categorized into China, Japan, India, Australia, South Korea, and the Rest of APAC. China is projected to expand at a CAGR of 6.7% during 2026 - 2034.

Key players operating in the Forced Oscillometry Market are COSMED Srl, Chest MI Inc, Morgan Scientific Inc, THORASYS Thoracic Medical Systems Inc., Jaeger Medical GmbH, IngMar Medical, GANSHORN Medizin Electronic GmbH, Lothar Medical GmbH, Cognita Labs, LLC, and RESTECH srl, among others.

• In December 2025, COSMED S.r.l., a global leader in Cardiopulmonary diagnostics, Metabolic assessment solutions, and Body Composition technologies, is pleased to announce the acquisition of Ergometrix S.A., a long-established Spanish distributor specialized in electronic equipment for the healthcare and rehabilitation sectors.